DE69132771D1 - Sonden für die detektion der p53 mutante - Google Patents

Sonden für die detektion der p53 mutante

Info

Publication number
DE69132771D1
DE69132771D1 DE69132771T DE69132771T DE69132771D1 DE 69132771 D1 DE69132771 D1 DE 69132771D1 DE 69132771 T DE69132771 T DE 69132771T DE 69132771 T DE69132771 T DE 69132771T DE 69132771 D1 DE69132771 D1 DE 69132771D1
Authority
DE
Germany
Prior art keywords
mutant
probe
detecting
cancer
mutants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69132771T
Other languages
English (en)
Other versions
DE69132771T2 (de
Inventor
J Levine
E Shenk
A Finlay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Princeton University
Original Assignee
Princeton University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Princeton University filed Critical Princeton University
Application granted granted Critical
Publication of DE69132771D1 publication Critical patent/DE69132771D1/de
Publication of DE69132771T2 publication Critical patent/DE69132771T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Investigating Or Analyzing Materials By The Use Of Magnetic Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69132771T 1990-06-27 1991-06-27 Sonden für die detektion der p53 mutante Expired - Lifetime DE69132771T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54396390A 1990-06-27 1990-06-27
PCT/US1991/004608 WO1992000311A1 (en) 1990-06-27 1991-06-27 Probes for detecting mutant p53

Publications (2)

Publication Number Publication Date
DE69132771D1 true DE69132771D1 (de) 2001-11-22
DE69132771T2 DE69132771T2 (de) 2002-08-01

Family

ID=24170243

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69133528T Expired - Lifetime DE69133528T2 (de) 1990-06-27 1991-06-27 Proteinkomplex p53/p90
DE69132771T Expired - Lifetime DE69132771T2 (de) 1990-06-27 1991-06-27 Sonden für die detektion der p53 mutante

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69133528T Expired - Lifetime DE69133528T2 (de) 1990-06-27 1991-06-27 Proteinkomplex p53/p90

Country Status (10)

Country Link
US (1) US5382510A (de)
EP (2) EP1013666B1 (de)
JP (3) JP3179481B2 (de)
AT (2) ATE325813T1 (de)
AU (1) AU8221191A (de)
CA (1) CA2064555A1 (de)
DE (2) DE69133528T2 (de)
DK (2) DK1013666T3 (de)
ES (2) ES2264239T3 (de)
WO (1) WO1992000311A1 (de)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362623A (en) * 1991-06-14 1994-11-08 The John Hopkins University Sequence specific DNA binding by p53
NO312681B1 (no) * 1990-08-24 2002-06-17 Univ California Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet
US6372424B1 (en) * 1995-08-30 2002-04-16 Third Wave Technologies, Inc Rapid detection and identification of pathogens
US5888780A (en) * 1992-12-07 1999-03-30 Third Wave Technologies, Inc. Rapid detection and identification of nucleic acid variants
US7326778B1 (en) * 1993-05-05 2008-02-05 The John Hopkins University Mutator gene and hereditary non-polyposis colorectal cancer
US6235470B1 (en) * 1993-11-12 2001-05-22 The Johns Hopkins University School Of Medicine Detection of neoplasia by analysis of saliva
US5561041A (en) * 1993-11-12 1996-10-01 The Johns Hopkins University School Of Medicine Nucleic acid mutation detection by analysis of sputum
US5622829A (en) * 1993-12-08 1997-04-22 The Regents Of The University Of California Genetic markers for breast, ovarian, and prostatic cancer
DE69528703T2 (de) * 1994-07-08 2003-07-17 Visible Genetics, Inc. VERFAHREN, REAGENZIEN UND TESTSATZ ZUR DIAGNOSE UND GEZIELTE SIEBTESTUNG FÜR p53 MÜTATIONEN
US5545527A (en) 1994-07-08 1996-08-13 Visible Genetics Inc. Method for testing for mutations in DNA from a patient sample
US5834181A (en) * 1994-07-28 1998-11-10 Genzyme Corporation High throughput screening method for sequences or genetic alterations in nucleic acids
AU686004B2 (en) * 1994-08-12 1998-01-29 Myriad Genetics, Inc. In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene
US5693473A (en) * 1994-08-12 1997-12-02 Myriad Genetics, Inc. Linked breast and ovarian cancer susceptibility gene
US5753441A (en) * 1994-08-12 1998-05-19 Myriad Genetics, Inc. 170-linked breast and ovarian cancer susceptibility gene
US5747282A (en) * 1994-08-12 1998-05-05 Myraid Genetics, Inc. 17Q-linked breast and ovarian cancer susceptibility gene
US5709999A (en) * 1994-08-12 1998-01-20 Myriad Genetics Inc. Linked breast and ovarian cancer susceptibility gene
ATE209660T1 (de) * 1994-08-12 2001-12-15 Myriad Genetics Inc 17q-verbundenes ovarial- und brustkrebs empfindlichkeitsgen
CA2203627C (en) * 1994-11-09 2000-06-06 James E. Dahlberg Rapid detection and identification of nucleic acid variants and pathogens
DE4444969C1 (de) * 1994-12-16 1996-10-24 Orga Med Dr Med Erwin Klopfer Nachweis von Antikörpern gegen p53 in Körperflüssigkeiten
US5707806A (en) * 1995-06-07 1998-01-13 Genzyme Corporation Direct sequence identification of mutations by cleavage- and ligation-associated mutation-specific sequencing
US5670325A (en) * 1996-08-14 1997-09-23 Exact Laboratories, Inc. Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
US5741650A (en) * 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US5821049A (en) * 1996-04-05 1998-10-13 Viratest Carcinogen Monitoring, Ltd In vitro assay for identification of carcinogens
US6153429A (en) * 1996-04-05 2000-11-28 Vera Genics Ltd. Cell lines useful for in vitro assay for indentification of carcinogens
US5955279A (en) * 1996-06-13 1999-09-21 Gatti; Richard A. Ataxia-telangiectasia: mutations in the ATM gene
US5858673A (en) * 1996-06-24 1999-01-12 Charlotte-Mecklenburg Hospital Authority Method for detecting prostate cells
US6020137A (en) * 1996-08-14 2000-02-01 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US5952178A (en) 1996-08-14 1999-09-14 Exact Laboratories Methods for disease diagnosis from stool samples
US6203993B1 (en) 1996-08-14 2001-03-20 Exact Science Corp. Methods for the detection of nucleic acids
US5928870A (en) * 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6146828A (en) * 1996-08-14 2000-11-14 Exact Laboratories, Inc. Methods for detecting differences in RNA expression levels and uses therefor
US6300077B1 (en) 1996-08-14 2001-10-09 Exact Sciences Corporation Methods for the detection of nucleic acids
US6100029A (en) * 1996-08-14 2000-08-08 Exact Laboratories, Inc. Methods for the detection of chromosomal aberrations
US5998136A (en) * 1996-08-19 1999-12-07 Arcaris, Inc. Selection systems and methods for identifying genes and gene products involved in cell proliferation
US6060240A (en) * 1996-12-13 2000-05-09 Arcaris, Inc. Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom
AT404993B (de) * 1997-01-13 1999-04-26 Immuno Ag Verfahren zur bestimmung eines proteins mit einer mutation
US5830665A (en) * 1997-03-03 1998-11-03 Exact Laboratories, Inc. Contiguous genomic sequence scanning
PT983510E (pt) * 1997-05-20 2004-06-30 Univ Erasmus Reconhecimento de produtos geneticos especificos de tumor em cancro
US6268136B1 (en) 1997-06-16 2001-07-31 Exact Science Corporation Methods for stool sample preparation
US6406857B1 (en) 1997-06-16 2002-06-18 Exact Sciences Corporation Methods for stool sample preparation
WO1999002682A1 (en) * 1997-07-09 1999-01-21 Affymetrix, Inc. p53 MUTANTS FOUND IN TUMORS
US20020064792A1 (en) * 1997-11-13 2002-05-30 Lincoln Stephen E. Database for storage and analysis of full-length sequences
US6531512B1 (en) * 1998-07-31 2003-03-11 Health Research Inc. Method of treating cancer in patients having a deficiency in p53 tumor suppressor gene
US6280947B1 (en) 1999-08-11 2001-08-28 Exact Sciences Corporation Methods for detecting nucleotide insertion or deletion using primer extension
US6503718B2 (en) 1999-01-10 2003-01-07 Exact Sciences Corporation Methods for detecting mutations using primer extension for detecting disease
DE60028732T2 (de) 1999-02-25 2007-06-14 Exact Sciences Corp., Maynard Verfahren zur erhaltung der dns-integrität
CA2366778C (en) * 1999-04-09 2008-07-22 Exact Sciences Corporation Methods for detecting nucleic acids indicative of cancer
EP1171595A1 (de) 1999-04-12 2002-01-16 Agensys, Inc. 13-transmembrane protein welches in prostatakrebs exprimiert wird
EP1792989A1 (de) 1999-04-12 2007-06-06 Agensys, Inc. 13-Transmembrane Protein welches in Prostatakrebs exprimiert wird
EP1200590B1 (de) 1999-08-12 2009-01-07 Agensys, Inc. C-typ lektin transmembranantigen, das in menschlichen prostatkrebs exprimiert wird, und deren verwendungen
US6849403B1 (en) 1999-09-08 2005-02-01 Exact Sciences Corporation Apparatus and method for drug screening
US6586177B1 (en) * 1999-09-08 2003-07-01 Exact Sciences Corporation Methods for disease detection
EP2003202B1 (de) 1999-10-05 2011-09-14 Agensys, Inc. G Protein-gekoppelter in Prostatakrebs hochexprimierter Rezeptor und seine Verwendungen
US6893818B1 (en) * 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
WO2001042781A2 (en) * 1999-12-07 2001-06-14 Exact Sciences Corporation Supracolonic aerodigestive neoplasm detection
US6919174B1 (en) 1999-12-07 2005-07-19 Exact Sciences Corporation Methods for disease detection
CA2415923C (en) 2000-07-12 2011-10-25 Agensys, Inc. Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers
ATE353366T1 (de) 2000-08-22 2007-02-15 Agensys Inc Nukleinsäure und protein, genannt 158p1d7, für die behandlung und erkennung von blasenkrebs und anderen krebsarten
DK1313850T3 (da) 2000-08-28 2008-12-01 Agensys Inc Nucleinsyre og tilsvarende protein med navnet 85PB3 anvendelige til behandling og påvisning af cancer
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US6428964B1 (en) 2001-03-15 2002-08-06 Exact Sciences Corporation Method for alteration detection
EP1573024A4 (de) 2001-04-10 2007-08-29 Agensys Inc Nukleinsäuren und diesen entprechende, für die behandlung und den nachweis verschiedener krebserkrankungen geeignete proteine
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
ES2537074T3 (es) 2001-09-06 2015-06-02 Agensys, Inc. Ácido nucleico y proteína correspondiente denominados STEAP-1 útiles en el tratamiento y la detección de cáncer
WO2003023398A1 (fr) * 2001-09-10 2003-03-20 The Kanagawa Academy Of Science And Technology Foundation Methode de criblage de medicament et methode de determination de l'importance d'une mutation dans un gene codant pour le facteur de regulation de la transcription
DK1456668T3 (da) 2001-12-05 2007-09-10 Sense Proteomic Ltd Proteinarrays til alleliske varianter og anvendelser deraf
US7776524B2 (en) * 2002-02-15 2010-08-17 Genzyme Corporation Methods for analysis of molecular events
DK1507556T3 (en) * 2002-05-02 2016-09-12 Wyeth Holdings Llc Calicheamicin derivative-carrier conjugates
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
JP2007524361A (ja) 2003-02-10 2007-08-30 アジェンシス， インコーポレイテッド 膀胱癌及びその他の癌の治療及び検出に有用な名称１５８ｐ１ｄ７の核酸及び対応タンパク質
JP2007525196A (ja) 2003-05-30 2007-09-06 アジェンシス， インコーポレイテッド 前立腺幹細胞抗原（ｐｓｃａ）変異体及びその部分配列
US20040259101A1 (en) * 2003-06-20 2004-12-23 Shuber Anthony P. Methods for disease screening
US20080241827A1 (en) * 2004-05-10 2008-10-02 Exact Sciences Corporation Methods For Detecting A Mutant Nucleic Acid
WO2005113769A1 (en) * 2004-05-14 2005-12-01 Exact Sciences Corporation Method for stabilizing biological samples for nucleic acid analysis
EP1753871B1 (de) 2004-05-28 2015-07-15 Agensys, Inc. An psca-proteine bindende antikörper und verwandte moleküle
US7981607B2 (en) * 2004-08-27 2011-07-19 Esoterix Genetic Laboratories LLC Method for detecting recombinant event
WO2006047787A2 (en) 2004-10-27 2006-05-04 Exact Sciences Corporation Method for monitoring disease progression or recurrence
KR20080003390A (ko) 2005-03-31 2008-01-07 어젠시스 인코포레이티드 161ｐ2ｆ10ｂ 단백질과 결합하는 항체 및 관련 분자
US9777314B2 (en) * 2005-04-21 2017-10-03 Esoterix Genetic Laboratories, Llc Analysis of heterogeneous nucleic acid samples
US7572586B2 (en) * 2005-11-01 2009-08-11 Mayo Foundation For Medical Education And Research Identifying susceptibility to cardiac hypertrophy
DE602006019128D1 (de) * 2005-11-10 2011-02-03 Bristol Myers Squibb Pharma Co Moesin, caveolin 1 und yes-assoziiertes protein 1 als prädiktive marker der reaktion auf dasatinib bei brustkrebs
US20140194310A1 (en) 2011-05-24 2014-07-10 Daniel H. Geschwind Genes dysregulated in autism as biomarkers and targets for therapeutic pathways
CN104080926B (zh) * 2011-10-28 2019-04-23 米伦纽姆医药公司 对nedd8活化酶(nae)抑制剂的反应的生物标记
CN105190656B (zh) 2013-01-17 2018-01-16 佩索纳里斯公司 用于遗传分析的方法和系统
GB2534067B (en) 2013-08-30 2021-07-21 Personalis Inc Methods and systems for genomic analysis
WO2015051275A1 (en) 2013-10-03 2015-04-09 Personalis, Inc. Methods for analyzing genotypes
WO2016070131A1 (en) 2014-10-30 2016-05-06 Personalis, Inc. Methods for using mosaicism in nucleic acids sampled distal to their origin
EP3465501A4 (de) 2016-05-27 2020-02-26 Personalis, Inc. Personalisierte gentests
US11299783B2 (en) 2016-05-27 2022-04-12 Personalis, Inc. Methods and systems for genetic analysis
GB201617564D0 (en) 2016-10-17 2016-11-30 Agency For Science Technology And Research And National University Of Singapore And Singapore Health Anti-p53 antibodies
US10801064B2 (en) 2018-05-31 2020-10-13 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
US11814750B2 (en) 2018-05-31 2023-11-14 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
WO2024137664A1 (en) * 2022-12-22 2024-06-27 Regents Of The University Of Minnesota Methods for detecting glioblastoma in extracellular vesicles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535058A (en) * 1982-10-01 1985-08-13 Massachusetts Institute Of Technology Characterization of oncogenes and assays based thereon
US4798787A (en) * 1984-09-19 1989-01-17 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
US4762706A (en) * 1984-10-17 1988-08-09 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
US4871838A (en) * 1985-07-23 1989-10-03 The Board Of Rijks Universiteit Leiden Probes and methods for detecting activated ras oncogenes
US4794075A (en) * 1985-08-29 1988-12-27 Lifecodes Corporation Method for locating and purifying DNA containing single base mismatches

Also Published As

Publication number Publication date
ATE325813T1 (de) 2006-06-15
EP1013666B1 (de) 2006-05-10
JP2001128691A (ja) 2001-05-15
EP0489149A4 (en) 1993-03-10
DE69133528D1 (de) 2006-06-14
EP0489149B1 (de) 2001-10-17
US5382510A (en) 1995-01-17
JP3711220B2 (ja) 2005-11-02
CA2064555A1 (en) 1991-12-28
JPH05505241A (ja) 1993-08-05
JP3179481B2 (ja) 2001-06-25
EP1013666A3 (de) 2000-07-05
AU8221191A (en) 1992-01-23
WO1992000311A1 (en) 1992-01-09
JP2000184888A (ja) 2000-07-04
DE69132771T2 (de) 2002-08-01
ATE207075T1 (de) 2001-11-15
DK1013666T3 (da) 2006-08-14
ES2164045T3 (es) 2002-02-16
EP1013666A2 (de) 2000-06-28
DK0489149T3 (da) 2001-12-27
DE69133528T2 (de) 2006-09-07
EP0489149A1 (de) 1992-06-10
ES2264239T3 (es) 2006-12-16

Similar Documents

Publication Publication Date Title
DE69132771D1 (de) Sonden für die detektion der p53 mutante
EP0390323A3 (de) Nachweis des Ausfalls des Wildtyps des p53-Gens
ATE209660T1 (de) 17q-verbundenes ovarial- und brustkrebs empfindlichkeitsgen
AU4355085A (en) Junction-fragment dna probes and probe clusters
DK0705903T3 (da) Mutationer i det 17q-koblede bryst- og ovariecancerprædisponeringen
PT75676A (en) Test method for the laboratory diagnosis of neisseria gonorrhoeae test strain of neisseria gonorrhoeae and test kit
IL71699A0 (en) Methods and kits for the analysis and detection of biological or genetic material
KR900700621A (ko) 돌연변이 유도물 및 발암물질에 대한 전달 유전성 검사시스템
GB2235769B (en) Detection of inherited disease alleles in DNA samples using yeast artificial chromosomes
GB2212907B (en) Device for making non-contacting measurements of electric fields which are static and/or varying in time
DE3068908D1 (en) Eddy current inspection apparatus and probe
DE3564865D1 (en) Method and eddy current probe for the examination of screws
GB2248298B (en) Probes,kits and methods for the detection and differentiation of mycobacteria
FR2468921B1 (fr) Perfectionnements apportes aux procede et appareils pour la determination des conditions et de l'homogeneite de la structure d'une veine de charbon
FI990380A0 (fi) Diagnostinen ja seulontamenetelmä
FI935579A (fi) Kemiluminesenssileimattuja geenikoettimia ja niiden käyttö geenikoetinkokeissa
BE871745A (fr) Procede d'amelioration des proprietes des gruaux et farines de graines oleagineuses
FR2556463B1 (fr) Extensometre permettant de mesurer directement et simultanement la deformation axiale et la distorsion d'une eprouvette
Günther Gene frequencies of human red cell phosphoglucomutase (PGM3) in Western Germany (Düsseldorf region)
Rueff et al. Assessment of the urinary inducing activity of SOS functions in E. coli using the SOS chromotest
GB2059068B (en) Apparatus for sensing and/or measuring changes in inclination
Papenfuss Recommendation for application of the depth of profile for the description of the surface roughness of cast products
Obe et al. Tests for Assessing the Mutagenic Action of Drugs in Man.
AU589116B2 (en) Electrical measuring apparatus, and methods for determining the condition or identity of biological material
Levine et al. Methods of diagnosing pre-cancer or cancer states using probes for detecting mutant P53

Legal Events

Date Code Title Description
8364 No opposition during term of opposition